Mini review: The clinical avenues of combined hydralazine-nitrate in subjects with heart failure with reduced ejection fraction

Background: Combined hydralazine-nitrate has an avenue in the management of subjects with heart failure reduced ejection fraction. Exploring pharmacotherapy this context will facilitate clinical utility combined therapy. Objective: The main objective mini-review was to evaluate role Methods: We conducted a literature search on Google scholar, MEDLINE, and PubMed identify randomized trials hydralazine-nitrate, 2760 articles were returned initially out which 10 conforming inclusion criteria. However, three trails focus for current mini-review. Key findings: lends support use fraction (HFrEF). combination may offer who have remained symptomatic HFrEF despite optimum dosing standard Black proved benefit from hydralazine-nitrate. (e.g. small dose hydralazine 12.5-25 mg twice day isosorbide mononitrate day) provide alternative contraindications (renal artery stenosis, creatinine clearance less than 30 mL/minute, sustained hyperkalemia) ACEinh, ARBs, and/or ARNI. Subjects should be assessed monitored systolic BP (keep >120 mmHg) chronic kidney disease eGFR > mL/min/1.73 m2). Hydralazine-nitrate inferior ACEinh (higher all-cause mortality cardiovascular mortality. Conclusion: minireview provides key points fraction..